Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial

PURPOSE: Erlotinib has been the only targeted agent to show significantly improved outcomes in pancreatic adenocarcinoma when combined with gemcitabine. We aimed to evaluate whether the addition of oxaliplatin to a combination gemcitabine/erlotinib treatment conferred a clinical benefit in patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Yonsei Med J
Main Authors: Lim, Sung Hee, Yun, Jina, Lee, Min-Young, Kim, Han Jo, Kim, Kyoung Ha, Kim, Se Hyung, Lee, Sang-Chul, Bae, Sang Byung, Kim, Chan Kyu, Lee, Namsu, Lee, Kyu Taek, Park, Seong Kyu, Lee, Yun Nah, Moon, Jong Ho
Format: Artigo
Jezik:Inglês
Izdano: Yonsei University College of Medicine 2021
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8298866/
https://ncbi.nlm.nih.gov/pubmed/34296544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2021.62.8.671
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki